Abstract
Telmisartan (TEL) is one of the angiotensin II receptor blockers. Although the anti-proteinuria effect of TEL in cats with chronic kidney disease has been reported, its effect in dogs has not been studied. In this study, we evaluated the anti-proteinuria effect and the adverse events of TEL in dogs with protein-losing nephropathy (PLN). TEL’s anti-proteinuria effect was also demonstrated in dogs with PLN. Moreover, some of the cases included in this study obtained remission of proteinuria (urine protein-to-creatinine ratio <0.5). The hyperpotassemia was most frequently observed as adverse events.
